Table 1.
Antibiotic susceptibility testing of 63 Acinetobacter baumannii isolates at the National Hospital of Tropical Diseases (Hanoi, Vietnam), 2009.
| Antibiotic | Susceptible |
Intermediate |
Resistant |
|||
|---|---|---|---|---|---|---|
| % | n | % | n | % | n | |
| AMC | 0.0 | 0 | 0.0 | 0 | 100.0 | 63 |
| TZP | 1.6 | 1 | 3.2 | 2 | 95.2 | 60 |
| Cefotaxime | 0.0 | 0 | 1.6 | 1 | 98.4 | 62 |
| Ceftazidime | 0.0 | 0 | 1.6 | 1 | 98.4 | 62 |
| Cefepime | 0.0 | 0 | 1.6 | 1 | 98.4 | 62 |
| Imipenem | 7.9 | 5 | 0.0 | 0 | 92.1 | 58 |
| Meropenem | 7.9 | 5 | 0.0 | 0 | 92.1 | 58 |
| Gentamicin | 17.5 | 11 | 27.0 | 17 | 55.6 | 35 |
| Tobramycin | 31.7 | 20 | 25.4 | 16 | 42.9 | 27 |
| Ciprofloxacin | 1.6 | 1 | 0.0 | 0 | 98.4 | 62 |
| Levofloxacin | 1.6 | 1 | 7.9 | 5 | 90.5 | 57 |
| Tigecycline | 58.7 | 37 | 38.1 | 24 | 3.2 | 2 |
| Colistin | 100.0 | 63 | 0.0 | 0 | 0.0 | 0 |
| SXT | 0.0 | 0 | 0.0 | 0 | 100.0 | 63 |
AMC, amoxicillin/clavulanic acid; TZP, piperacillin/tazobactam; SXT, trimethoprim/sulfamethoxazole.